409 related articles for article (PubMed ID: 28794043)
1. Sorafenib Impedes Rift Valley Fever Virus Egress by Inhibiting Valosin-Containing Protein Function in the Cellular Secretory Pathway.
Brahms A; Mudhasani R; Pinkham C; Kota K; Nasar F; Zamani R; Bavari S; Kehn-Hall K
J Virol; 2017 Nov; 91(21):. PubMed ID: 28794043
[TBL] [Abstract][Full Text] [Related]
2. Protein Phosphatase-1 regulates Rift Valley fever virus replication.
Baer A; Shafagati N; Benedict A; Ammosova T; Ivanov A; Hakami RM; Terasaki K; Makino S; Nekhai S; Kehn-Hall K
Antiviral Res; 2016 Mar; 127():79-89. PubMed ID: 26801627
[TBL] [Abstract][Full Text] [Related]
3. A Genome-Wide RNA Interference Screen Identifies a Role for Wnt/β-Catenin Signaling during Rift Valley Fever Virus Infection.
Harmon B; Bird SW; Schudel BR; Hatch AV; Rasley A; Negrete OA
J Virol; 2016 Aug; 90(16):7084-7097. PubMed ID: 27226375
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib-mediated targeting of the AAA⁺ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death.
Yi P; Higa A; Taouji S; Bexiga MG; Marza E; Arma D; Castain C; Le Bail B; Simpson JC; Rosenbaum J; Balabaud C; Bioulac-Sage P; Blanc JF; Chevet E
Mol Cancer Ther; 2012 Dec; 11(12):2610-20. PubMed ID: 23041544
[TBL] [Abstract][Full Text] [Related]
5. Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection.
Benedict A; Bansal N; Senina S; Hooper I; Lundberg L; de la Fuente C; Narayanan A; Gutting B; Kehn-Hall K
Front Microbiol; 2015; 6():676. PubMed ID: 26217313
[TBL] [Abstract][Full Text] [Related]
6. Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates.
Terasaki K; Tercero BR; Makino S
Virus Res; 2016 May; 216():55-65. PubMed ID: 26022573
[TBL] [Abstract][Full Text] [Related]
7. Limiting viral replication in hepatocytes alters Rift Valley fever virus disease manifestations.
Xu L; Paine AC; Barbeau DJ; Alencastro F; Duncan AW; McElroy AK
J Virol; 2023 Sep; 97(9):e0085323. PubMed ID: 37695055
[TBL] [Abstract][Full Text] [Related]
8. Creation of Rift Valley fever viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging.
Wichgers Schreur PJ; Oreshkova N; Moormann RJ; Kortekaas J
J Virol; 2014 Sep; 88(18):10883-93. PubMed ID: 25008937
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin modulation of p70 S6 kinase signaling inhibits Rift Valley fever virus pathogenesis.
Bell TM; Espina V; Senina S; Woodson C; Brahms A; Carey B; Lin SC; Lundberg L; Pinkham C; Baer A; Mueller C; Chlipala EA; Sharman F; de la Fuente C; Liotta L; Kehn-Hall K
Antiviral Res; 2017 Jul; 143():162-175. PubMed ID: 28442428
[TBL] [Abstract][Full Text] [Related]
10. A Haploid Genetic Screen Identifies Heparan Sulfate Proteoglycans Supporting Rift Valley Fever Virus Infection.
Riblett AM; Blomen VA; Jae LT; Altamura LA; Doms RW; Brummelkamp TR; Wojcechowskyj JA
J Virol; 2016 Feb; 90(3):1414-23. PubMed ID: 26581979
[TBL] [Abstract][Full Text] [Related]
11. [Study on DNA immune of envelope protein gene of Rift Valley Fever Virus].
Wang QH; Wang XJ; Hu S; Ge JY; Bu ZG
Wei Sheng Wu Xue Bao; 2007 Aug; 47(4):677-81. PubMed ID: 17944371
[TBL] [Abstract][Full Text] [Related]
12. The role of signal transducer and activator of transcription 3 in Rift Valley fever virus infection.
Pinkham C; An S; Lundberg L; Bansal N; Benedict A; Narayanan A; Kehn-Hall K
Virology; 2016 Sep; 496():175-185. PubMed ID: 27318793
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the Molecular Interactions That Govern the Packaging of Viral RNA Segments into Rift Valley Fever Phlebovirus Particles.
Tercero B; Narayanan K; Terasaki K; Makino S
J Virol; 2021 Jun; 95(14):e0042921. PubMed ID: 33952635
[TBL] [Abstract][Full Text] [Related]
14. Peripheral Blood Biomarkers of Disease Outcome in a Monkey Model of Rift Valley Fever Encephalitis.
Wonderlich ER; Caroline AL; McMillen CM; Walters AW; Reed DS; Barratt-Boyes SM; Hartman AL
J Virol; 2018 Feb; 92(3):. PubMed ID: 29118127
[TBL] [Abstract][Full Text] [Related]
15. CK1 and PP1 regulate Rift Valley fever virus genome replication through L protein phosphorylation.
Bracci N; Baer A; Flor R; Petraccione K; Stocker T; Zhou W; Ammosova T; Dinglasan RR; Nekhai S; Kehn-Hall K
Antiviral Res; 2024 Jun; 226():105895. PubMed ID: 38679165
[TBL] [Abstract][Full Text] [Related]
16. Risk analysis of inter-species reassortment through a Rift Valley fever phlebovirus MP-12 vaccine strain.
Ly HJ; Lokugamage N; Nishiyama S; Ikegami T
PLoS One; 2017; 12(9):e0185194. PubMed ID: 28926632
[TBL] [Abstract][Full Text] [Related]
17. The pathogenesis of Rift Valley fever.
Ikegami T; Makino S
Viruses; 2011 May; 3(5):493-519. PubMed ID: 21666766
[TBL] [Abstract][Full Text] [Related]
18. Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment.
Scharton D; Bailey KW; Vest Z; Westover JB; Kumaki Y; Van Wettere A; Furuta Y; Gowen BB
Antiviral Res; 2014 Apr; 104():84-92. PubMed ID: 24486952
[TBL] [Abstract][Full Text] [Related]
19. High content image-based screening of a protease inhibitor library reveals compounds broadly active against Rift Valley fever virus and other highly pathogenic RNA viruses.
Mudhasani R; Kota KP; Retterer C; Tran JP; Whitehouse CA; Bavari S
PLoS Negl Trop Dis; 2014 Aug; 8(8):e3095. PubMed ID: 25144302
[TBL] [Abstract][Full Text] [Related]
20. The NSs Protein Encoded by the Virulent Strain of Rift Valley Fever Virus Targets the Expression of Abl2 and the Actin Cytoskeleton of the Host, Affecting Cell Mobility, Cell Shape, and Cell-Cell Adhesion.
Bamia A; Marcato V; Boissière M; Mansuroglu Z; Tamietti C; Romani M; Simon D; Tian G; Niedergang F; Panthier JJ; Flamand M; Souès S; Bonnefoy E
J Virol; 2020 Dec; 95(1):. PubMed ID: 33087469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
